Clinical Genetics 1997-03-01

Two novel mutations in a Canadian family with aspartylglucosaminuria and early outcome post bone marrow transplantation.

A Laitinen, M Hietala, J C Haworth, M L Schroeder, L E Seargeant, C R Greenberg, P Aula

Index: Clin. Genet. 51(3) , 174-8, (1997)

Full Text: HTML

Abstract

Aspartylglucosaminuria (AGU) is a lysosomal storage disease caused by deficiency of aspartylglucosaminidase. The disease is overrepresented in the Finnish population, in which one missense mutation (Cys163Ser) is responsible for 98% of the disease alleles. The few non-Finnish cases of AGU which have been analyzed at molecular level have revealed a spectrum of different mutations. Here, we report two new missense mutations causing AGU in two Canadian siblings. The patients were compound heterozygotes with a G299-->A transition causing a Gly100-->Gln substitution and a T404-->C transition resulting in a Phe135-->Ser change in the cDNA coding for aspartylglucosaminidase. The younger patient recently underwent bone marrow transplantation.

Related Compounds

  • N-Asn

Related Articles:

Synthesis of N4-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparagine analogues. n-Butyramide, 3-chloropropionamide, 3-aminopropionamide, and isovaleramide analogues.

2001-04-23

[Carbohydr. Res. 331(4) , 439-44, (2001)]

Aspartylglycosaminuria: biochemistry and molecular biology.

1999-10-08

[Biochim. Biophys. Acta 1455(2-3) , 139-54, (1999)]

Angiokeratoma corporis diffusum in a Spanish patient with aspartylglucosaminuria.

2002-10-01

[Br. J. Dermatol. 147(4) , 760-4, (2002)]

Bilateral pulvinar signal intensity decrease on T2-weighted images in patients with aspartylglucosaminuria.

2008-07-01

[Acta radiol. 49(6) , 687-92, (2008)]

Synthesis of an N-glucoasparagine analog as a building block for a V3-loop glycopeptide from gp120 of HIV-I.

1998-12-01

[Carbohydr. Res. 313(2) , 107-16, (1998)]

More Articles...